Cancer:腭扁桃体鳞状细胞癌单边和双边调强放射治疗比较

2017-09-25 AlexYang MedSci原创

最近,有作者提出了这样的一个假设,即对患有单侧性的腭扁桃体癌和N0到N2b疾病分级且具有相似肿瘤结果的病人来说,单边调强放射治疗(IMRT)与双边IMRT相比会减少毒性。研究有154名病人在1997年到2013年接受了术后IMRT治疗。研究人眼前瞻性的收集了2005年到2013年的数据,并且回顾性的收集了2005年前的数据。对那些患有单侧性初级和N0到N2b颈部分级的病人,48名病人接受了单边IM

最近,有作者提出了这样的一个假设,即对患有单侧性的腭扁桃体癌和N0到N2b疾病分级且具有相似肿瘤结果的病人来说,单边调强放射治疗(IMRT)与双边IMRT相比会减少毒性。研究有154名病人在1997年到2013年接受了术后IMRT治疗。研究人眼前瞻性的收集了2005年到2013年的数据,并且回顾性的收集了2005年前的数据。对那些患有单侧性初级和N0到N2b颈部分级的病人,48名病人接受了单边IMRT(组1)和59名病人接受了双边IMRT(组2)。另外,总共有47名病人具有非单侧性初级或者N2c到N3疾病并且接受了双边IMRT(组3)。

研究的跟踪调查时间均值为5.5年。研究发现,在5年的局部区域控制率在组1、组2和组3之间相似(分别为100%, 96%和 94%; pooled comparison: P=0.39,组1 vs 组2 comparison: P=0.19)。另外,5年总的生存率在组1、组2和组3之间相似(分比为85%, 79%和76%;pooled comparison: P=0.60 组 1 vs 组 2 comparison: P=0.25)。在单边治疗病人中,并没有出现对侧颈部复发情况出现。与双边IMRT比较,单边IMRT减少了急性中毒并且改善了病人报道的生活质量。

最后,研究人员指出,在选择的患有单侧性腭扁桃体癌并且具有N0到N2b颈部分级的病人中,单边IMRT可以减少急性中毒并且可以获得与双边IMRT相似的肿瘤治疗结果。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813315, encodeId=4e9a181331543, content=<a href='/topic/show?id=93c791998fd' target=_blank style='color:#2F92EE;'>#调强放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91998, encryptionId=93c791998fd, topicName=调强放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sat Sep 08 14:56:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978575, encodeId=fa3219e857583, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Mar 21 22:56:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630243, encodeId=7ac0163024347, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Wed Sep 27 11:56:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247784, encodeId=545824e784f8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Sep 26 06:57:46 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247782, encodeId=76b424e78256, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Sep 26 06:55:45 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247682, encodeId=132524e682eb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Sep 25 22:46:34 CST 2017, time=2017-09-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813315, encodeId=4e9a181331543, content=<a href='/topic/show?id=93c791998fd' target=_blank style='color:#2F92EE;'>#调强放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91998, encryptionId=93c791998fd, topicName=调强放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sat Sep 08 14:56:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978575, encodeId=fa3219e857583, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Mar 21 22:56:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630243, encodeId=7ac0163024347, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Wed Sep 27 11:56:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247784, encodeId=545824e784f8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Sep 26 06:57:46 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247782, encodeId=76b424e78256, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Sep 26 06:55:45 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247682, encodeId=132524e682eb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Sep 25 22:46:34 CST 2017, time=2017-09-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813315, encodeId=4e9a181331543, content=<a href='/topic/show?id=93c791998fd' target=_blank style='color:#2F92EE;'>#调强放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91998, encryptionId=93c791998fd, topicName=调强放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sat Sep 08 14:56:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978575, encodeId=fa3219e857583, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Mar 21 22:56:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630243, encodeId=7ac0163024347, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Wed Sep 27 11:56:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247784, encodeId=545824e784f8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Sep 26 06:57:46 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247782, encodeId=76b424e78256, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Sep 26 06:55:45 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247682, encodeId=132524e682eb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Sep 25 22:46:34 CST 2017, time=2017-09-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1813315, encodeId=4e9a181331543, content=<a href='/topic/show?id=93c791998fd' target=_blank style='color:#2F92EE;'>#调强放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91998, encryptionId=93c791998fd, topicName=调强放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sat Sep 08 14:56:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978575, encodeId=fa3219e857583, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Mar 21 22:56:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630243, encodeId=7ac0163024347, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Wed Sep 27 11:56:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247784, encodeId=545824e784f8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Sep 26 06:57:46 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247782, encodeId=76b424e78256, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Sep 26 06:55:45 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247682, encodeId=132524e682eb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Sep 25 22:46:34 CST 2017, time=2017-09-25, status=1, ipAttribution=)]
    2017-09-26 半夏微凉

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1813315, encodeId=4e9a181331543, content=<a href='/topic/show?id=93c791998fd' target=_blank style='color:#2F92EE;'>#调强放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91998, encryptionId=93c791998fd, topicName=调强放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sat Sep 08 14:56:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978575, encodeId=fa3219e857583, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Mar 21 22:56:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630243, encodeId=7ac0163024347, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Wed Sep 27 11:56:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247784, encodeId=545824e784f8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Sep 26 06:57:46 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247782, encodeId=76b424e78256, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Sep 26 06:55:45 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247682, encodeId=132524e682eb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Sep 25 22:46:34 CST 2017, time=2017-09-25, status=1, ipAttribution=)]
    2017-09-26 三生有幸9135

    学习一下谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1813315, encodeId=4e9a181331543, content=<a href='/topic/show?id=93c791998fd' target=_blank style='color:#2F92EE;'>#调强放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91998, encryptionId=93c791998fd, topicName=调强放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sat Sep 08 14:56:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978575, encodeId=fa3219e857583, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Mar 21 22:56:00 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630243, encodeId=7ac0163024347, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Wed Sep 27 11:56:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247784, encodeId=545824e784f8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Tue Sep 26 06:57:46 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247782, encodeId=76b424e78256, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Sep 26 06:55:45 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247682, encodeId=132524e682eb, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Sep 25 22:46:34 CST 2017, time=2017-09-25, status=1, ipAttribution=)]
    2017-09-25 Y—xianghai

    学习了新知识

    0

相关资讯

外媒称人体“多余”器官大有用处:阑尾可抵抗癌症

外媒称,过去人们认为,脾脏不太重要,而扁桃体和阑尾更是毫无用处——是返祖现象和退化器官。现代医学是如何看待这一问题的?

扁桃体干细胞或可用于肝脏损伤治疗

研究表明肝脏对身体来说具有非常重要的作用,比如它能清除身体毒素。缺少肝脏对人体来说是致命的,如果它受到损害,相对来说是很难治愈的。但是科学家们发表在ACS Applied Materials & Interfaces 杂志上的文章指出可以抽取扁桃体中的干细胞(这一部分是我们身体所不需要的)来修复受损肝脏器官,且全程无需动手术便可实施。 Byeongmoon Jeong 和他的同事们指

警惕:难缠的咽痛——扁桃体周围脓肿

临床工作中,遇到难缠逐渐加重的咽痛,切勿以为都是急性扁桃体炎,应警惕扁桃体周围脓肿的形成,早期发现,早期抽脓!

Int Arch Otorhinolaryngol:抽烟对慢性/复发性扁桃体炎和扁桃腺切除术后出血的影响

抽烟对口腔和咽黏膜有着许多的不良作用。结果可能是发展成为扁桃体感染和诱导扁桃腺切除术后出血(PTB)。最近,有研究人员就是否抽烟者患有更多的慢性/复发性扁桃体炎或者发展成为更多的PTB进行了研究。研究采用了一种回顾性的研究,包括了两个成年人组。组1为因慢性/复发性扁桃体炎而经历了扁桃腺切除术的抽烟者;组2为慢性/复发性扁桃体炎PTB需要控制抽烟量的病人群体。组1主要作为组2的群体参照。研究人员从医

NEJM病例:腮腺肿瘤引起的扁桃体不对称

该病例发表在2014年3月27日刊《新英格兰医学杂志》上。 女,28岁,平素健康,因近期发现扁桃体不对称求诊。其左侧脸颊有一细小的无痛性肿物,并在过去数月间缓慢增大。查体发现左侧扁桃体向中线移位(图A,箭头),并证实左下颌后区域内有一质硬、不可推动的肿物。无颈淋巴结肿大或面神经异常。T2加权的核磁共振成像(MRI)可见左侧腮腺有一高密度肿瘤(图B,冠状位,箭头),大小约为6 cm×4

说说肾病患者扁桃体那些事儿

扁桃体是人体免疫活性器官之一,它可产生淋巴细胞和抗体直接对抗入侵体内的细菌和病毒,就如同一个个卫士镇守在人体与外界接触的边防要塞。